دورية أكاديمية
أعرض في EDS

BARD1 mystery: tumor suppressors are cancer susceptibility genes.

التفاصيل البيبلوغرافية
العنوان: BARD1 mystery: tumor suppressors are cancer susceptibility genes.
المؤلفون: Hawsawi YM; King Faisal Specialist Hospital and Research Center- Research Center, KFSH&RC, MBC-J04, P.O. Box 40047, Jeddah, 21499, Saudi Arabia. hyousef@kfshrc.edu.sa.; College of Medicine, Al-Faisal University, P.O. Box 50927, Riyadh, 11533, Saudi Arabia. hyousef@kfshrc.edu.sa., Shams A; Department of Pharmacology, College of Medicine, Taif University, P.O. Box 11099, Taif, 21944, Saudi Arabia., Theyab A; College of Medicine, Al-Faisal University, P.O. Box 50927, Riyadh, 11533, Saudi Arabia.; Department of Pharmacology, College of Medicine, Taif University, P.O. Box 11099, Taif, 21944, Saudi Arabia.; Department of Laboratory Medicine, Security Forces Hospital, Mecca, Kingdom of Saudi Arabia., Abdali WA; King Faisal Specialist Hospital and Research Center- Research Center, KFSH&RC, MBC-J04, P.O. Box 40047, Jeddah, 21499, Saudi Arabia., Hussien NA; Department of Zoology, Faculty of Science, Cairo University, Giza, 12613, Egypt.; Department of Biology, College of Science, Taif University, P.O Box 11099, Taif, 21944, Saudi Arabia., Alatwi HE; Department of Biology, Faculty of Sciences, University of Tabuk, Tabuk, Kingdom of Saudi Arabia.; Genome and Biotechnology Unit, Faculty of Science, University of Tabuk, Tabuk, Saudi Arabia., Alzahrani OR; Department of Biology, Faculty of Sciences, University of Tabuk, Tabuk, Kingdom of Saudi Arabia.; Genome and Biotechnology Unit, Faculty of Science, University of Tabuk, Tabuk, Saudi Arabia., Oyouni AAA; Department of Biology, Faculty of Sciences, University of Tabuk, Tabuk, Kingdom of Saudi Arabia.; Genome and Biotechnology Unit, Faculty of Science, University of Tabuk, Tabuk, Saudi Arabia., Babalghith AO; Medical genetics Department, College of Medicine, Umm Alqura University, Makkah, Saudi Arabia., Alreshidi M; Departement of biology, College of Science, University of Hail, Hail, Saudi Arabia.; Molecular Diagnostic and Personalized Therapeutic Unit, University of Hail, Hail, Saudi Arabia.
المصدر: BMC cancer [BMC Cancer] 2022 Jun 01; Vol. 22 (1), pp. 599. Date of Electronic Publication: 2022 Jun 01.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : BioMed Central, [2001-
مواضيع طبية MeSH: Neoplasms*/genetics , Tumor Suppressor Proteins*/genetics , Tumor Suppressor Proteins*/metabolism , Ubiquitin-Protein Ligases*/genetics , Ubiquitin-Protein Ligases*/metabolism, Female ; Genes, Tumor Suppressor ; Humans ; Protein Isoforms/genetics
مستخلص: The full-length BRCA1-associated RING domain 1 (BARD1) gene encodes a 777-aa protein. BARD1 displays a dual role in cancer development and progression as it acts as a tumor suppressor and an oncogene. Structurally, BARD1 has homologous domains to BRCA1 that aid their heterodimer interaction to inhibit the progression of different cancers such as breast and ovarian cancers following the BRCA1-dependant pathway. In addition, BARD1 was shown to be involved in other pathways that are involved in tumor suppression (BRCA1-independent pathway) such as the TP53-dependent apoptotic signaling pathway. However, there are abundant BARD1 isoforms exist that are different from the full-length BARD1 due to nonsense and frameshift mutations, or deletions were found to be associated with susceptibility to various cancers including neuroblastoma, lung, breast, and cervical cancers. This article reviews the spectrum of BARD1 full-length genes and its different isoforms and their anticipated associated risk. Additionally, the study also highlights the role of BARD1 as an oncogene in breast cancer patients and its potential uses as a prognostic/diagnostic biomarker and as a therapeutic target for cancer susceptibility testing and treatment.
(© 2022. The Author(s).)
References: Database (Oxford). 2013 Jan 15;2013:bas060. (PMID: 23325629)
Science. 2011 Oct 28;334(6055):525-8. (PMID: 22034435)
Cancers (Basel). 2019 Oct 10;11(10):. (PMID: 31658720)
Science. 1999 Sep 3;285(5433):1576-9. (PMID: 10477523)
J Biol Chem. 2008 Jul 25;283(30):21179-86. (PMID: 18480049)
Mol Cell Biol. 2003 Jul;23(14):5056-63. (PMID: 12832489)
Trends Biochem Sci. 1999 Aug;24(8):311-6. (PMID: 10431175)
Science. 2003 Oct 24;302(5645):639-42. (PMID: 14576433)
Breast Cancer Res Treat. 2008 Oct;111(3):505-9. (PMID: 17972171)
PLoS One. 2011 Mar 21;6(3):e17911. (PMID: 21445301)
Sci Rep. 2022 Jan 26;12(1):1405. (PMID: 35082362)
Nat Rev Cancer. 2009 Sep;9(9):631-43. (PMID: 19701242)
Genes (Basel). 2020 Oct 24;11(11):. (PMID: 33114377)
Int J Cancer. 2012 Jul 1;131(1):83-94. (PMID: 21815143)
Genes (Basel). 2017 Dec 08;8(12):. (PMID: 29292755)
J Biol Chem. 2002 Jun 14;277(24):21315-24. (PMID: 11925436)
Cell. 1997 Aug 8;90(3):425-35. (PMID: 9267023)
J Cancer. 2019 May 21;10(10):2153-2160. (PMID: 31258718)
J Cell Biochem. 2018 Oct 8;:. (PMID: 30298630)
EMBO J. 2000 Feb 15;19(4):662-71. (PMID: 10675335)
J Clin Oncol. 2005 Jun 10;23(17):3912-22. (PMID: 15851766)
Nat Commun. 2021 Feb 23;12(1):1243. (PMID: 33623049)
BMC Bioinformatics. 2013;14 Suppl 14:S9. (PMID: 24267009)
Cell. 2001 Mar 9;104(5):743-53. (PMID: 11257228)
Nucleic Acids Res. 2015 Jan;43(Database issue):D447-52. (PMID: 25352553)
J Natl Cancer Inst. 2018 Aug 1;110(8):855-862. (PMID: 30099541)
J Oncol. 2021 Oct 21;2021:6180337. (PMID: 34721579)
Ann Oncol. 2015 Jul;26(7):1291-9. (PMID: 25605744)
Genes (Basel). 2020 Jul 21;11(7):. (PMID: 32708251)
Mol Cell. 2018 Oct 4;72(1):127-139.e8. (PMID: 30244837)
J Clin Immunol. 2021 Jan;41(1):217-220. (PMID: 32986178)
Clin Cancer Res. 2011 Aug 15;17(16):5451-62. (PMID: 21693656)
Cancer Cell. 2013 May 13;23(5):693-704. (PMID: 23680151)
Oncologist. 2007 Oct;12(10):1247-52. (PMID: 17962618)
J Natl Cancer Inst. 1999 Jun 2;91(11):943-9. (PMID: 10359546)
Biochim Biophys Acta. 2013 Dec;1836(2):345-53. (PMID: 24189571)
Carcinogenesis. 2012 Nov;33(11):2007-17. (PMID: 22822097)
Oncogene. 2005 May 26;24(23):3726-36. (PMID: 15782130)
JAMA. 2017 Jun 20;317(23):2402-2416. (PMID: 28632866)
J Cell Biol. 1998 Nov 30;143(5):1329-39. (PMID: 9832560)
Cancer Epidemiol Biomarkers Prev. 2011 May;20(5):1032-8. (PMID: 21393566)
Clin Cancer Res. 2014 Feb 1;20(3):764-75. (PMID: 24240112)
J Biol Chem. 2002 Jul 19;277(29):25904-13. (PMID: 11994312)
Mol Genet Genomic Med. 2019 Sep;7(9):e879. (PMID: 31317679)
Breast Cancer Res Treat. 2012 Jan;131(1):89-97. (PMID: 21344236)
Int J Mol Sci. 2020 Feb 08;21(3):. (PMID: 32046255)
Int J Biochem Cell Biol. 2010 May;42(5):693-700. (PMID: 20060929)
Cancer Res. 2012 Apr 15;72(8):2068-78. (PMID: 22350409)
Mol Cell Biol. 2003 Nov;23(21):7926-36. (PMID: 14560035)
J Biol Chem. 2001 Nov 2;276(44):41399-406. (PMID: 11526114)
Nat Commun. 2019 Mar 15;10(1):1224. (PMID: 30874560)
Pharmacogenomics. 2020 Feb;21(3):157-161. (PMID: 31967517)
Anticancer Agents Med Chem. 2022;22(7):1397-1406. (PMID: 34165414)
Breast Cancer Res Treat. 2007 May;102(3):329-37. (PMID: 17028982)
Proc Natl Acad Sci U S A. 2011 Nov 1;108(44):18032-7. (PMID: 22006311)
J Breast Cancer. 2013 Dec;16(4):417-25. (PMID: 24454464)
Genes (Basel). 2020 Jul 27;11(8):. (PMID: 32726901)
Breast Cancer Res Treat. 2010 Oct;123(3):725-31. (PMID: 20020197)
Front Oncol. 2019 Oct 15;9:1011. (PMID: 31681566)
Nat Commun. 2018 Apr 23;9(1):1595. (PMID: 29686231)
PLoS Genet. 2019 Mar 29;15(3):e1008049. (PMID: 30925164)
Nat Biotechnol. 2007 Jan;25(1):84-90. (PMID: 17211407)
Breast Cancer Res. 2021 May 1;23(1):53. (PMID: 33933153)
Proc Natl Acad Sci U S A. 2018 Feb 6;115(6):1316-1321. (PMID: 29367421)
Eur J Hum Genet. 2006 Feb;14(2):167-72. (PMID: 16333312)
Nat Cell Biol. 2018 Apr;20(4):492-502. (PMID: 29593331)
Int J Cancer. 2006 Mar 1;118(5):1215-26. (PMID: 16152612)
Breast Cancer Res. 2019 Apr 29;21(1):55. (PMID: 31036035)
Sci Rep. 2018 Jul 26;8(1):11515. (PMID: 30046141)
Cancer Res. 2007 Dec 15;67(24):11876-85. (PMID: 18089818)
Cancer Res. 2009 Feb 1;69(3):1125-34. (PMID: 19176389)
Nat Genet. 1996 Dec;14(4):430-40. (PMID: 8944023)
Science. 2017 Aug 18;357(6352):. (PMID: 28818916)
Genes Cells. 2013 Dec;18(12):1120-30. (PMID: 24581343)
Sci Rep. 2020 Jul 23;10(1):12377. (PMID: 32704157)
Technol Cancer Res Treat. 2019 Jan-Dec;18:1533033819892260. (PMID: 31808361)
Mol Cell Endocrinol. 2007 Mar 15;267(1-2):106-15. (PMID: 17275994)
Cancers (Basel). 2019 May 28;11(6):. (PMID: 31142030)
Endocr Relat Cancer. 2018 Feb;25(2):R83-R113. (PMID: 29162647)
Cancer Lett. 2003 Oct 8;200(1):1-7. (PMID: 14550946)
EBioMedicine. 2017 Feb;16:101-105. (PMID: 28161399)
Mol Pharmacol. 2020 Jul;98(1):24-37. (PMID: 32362585)
PLoS One. 2018 Nov 2;13(11):e0203376. (PMID: 30388713)
JAMA Oncol. 2016 Apr;2(4):482-90. (PMID: 26720728)
Discov Med. 2016 May;21(117):411-27. (PMID: 27355337)
PLoS One. 2013 Dec 11;8(12):e83018. (PMID: 24349422)
Mol Genet Genomic Med. 2021 Jul;9(7):e1707. (PMID: 34036740)
Cancer Lett. 2012 Sep 28;322(2):148-58. (PMID: 22561557)
Breast Cancer Res Treat. 2009 May;115(1):145-50. (PMID: 18481171)
Proc Natl Acad Sci U S A. 2001 May 22;98(11):5952-4. (PMID: 11371630)
Hum Mol Genet. 1998 Feb;7(2):195-202. (PMID: 9425226)
Oncogene. 1999 Jun 3;18(22):3316-23. (PMID: 10362352)
Nat Rev Cancer. 2006 May;6(5):382-91. (PMID: 16633366)
Mol Cancer Res. 2008 Jul;6(7):1250-8. (PMID: 18644987)
Proc Natl Acad Sci U S A. 1997 Oct 28;94(22):12075-80. (PMID: 9342365)
JAMA Oncol. 2017 Sep 01;3(9):1190-1196. (PMID: 28418444)
J Med Genet. 2004 Sep;41(9):e114. (PMID: 15342711)
Mol Genet Genomic Med. 2022 Mar;10(3):e1847. (PMID: 35084806)
Technol Cancer Res Treat. 2018 Jan 1;17:1533033818806910. (PMID: 30343639)
Nucleic Acids Res. 2017 Dec 1;45(21):12100-12112. (PMID: 29036709)
J Med Chem. 2005 May 5;48(9):3344-53. (PMID: 15857140)
Nature. 2017 Nov 2;551(7678):92-94. (PMID: 29059683)
Nat Rev Mol Cell Biol. 2020 May;21(5):284-299. (PMID: 32094664)
Science. 2003 Oct 24;302(5645):636-9. (PMID: 14576432)
Science. 2005 Jan 14;307(5707):269-73. (PMID: 15653507)
Nat Cell Biol. 2010 Apr;12(4):372-9. (PMID: 20190740)
Cancer Cell. 2011 Dec 13;20(6):797-809. (PMID: 22172724)
Mol Biol Rep. 2012 Aug;39(8):8091-8. (PMID: 22544576)
Sci Rep. 2016 May 20;6:26273. (PMID: 27197561)
Oncotarget. 2016 May 31;7(22):32129-43. (PMID: 27050076)
Int J Biochem Cell Biol. 2010 Aug;42(8):1348-54. (PMID: 20227518)
Mol Cell. 2001 Dec;8(6):1255-66. (PMID: 11779501)
Genes Chromosomes Cancer. 2002 Mar;33(3):235-42. (PMID: 11807980)
Genes (Basel). 2020 Jul 15;11(7):. (PMID: 32679805)
PLoS Med. 2006 Jul;3(7):e217. (PMID: 16768547)
Lancet. 2011 Aug 27;378(9793):771-84. (PMID: 21802721)
Breast Cancer Res Treat. 2008 Jan;107(1):119-22. (PMID: 17333333)
Clin Med Res. 2009 Jun;7(1-2):4-13. (PMID: 19574486)
Int J Biochem Cell Biol. 2016 Mar;72:1-17. (PMID: 26738429)
Int J Biochem Cell Biol. 2010 Aug;42(8):1316-29. (PMID: 19800023)
فهرسة مساهمة: Keywords: BARD1; Breast Cancer; Oncogene; Tumor suppressor
المشرفين على المادة: 0 (Protein Isoforms)
0 (Tumor Suppressor Proteins)
EC 2.3.2.27 (BARD1 protein, human)
EC 2.3.2.27 (Ubiquitin-Protein Ligases)
تواريخ الأحداث: Date Created: 20220601 Date Completed: 20220603 Latest Revision: 20220716
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC9161512
DOI: 10.1186/s12885-022-09567-4
PMID: 35650591
قاعدة البيانات: MEDLINE
الوصف
تدمد:1471-2407
DOI:10.1186/s12885-022-09567-4